However, the synergy of the VEGF-inhibitor bevacizumab with the PD-L1 inhibitor atezolizumab appears to overcome the IO-resistance of oncogene-driven NSCLC, which is in part mediated by VEGF induced by oncogenic signaling [111]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.